Wolfson Institute of Preventive Medicine, Barts and London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.
J Med Screen. 2012 Mar;19(1):51-4. doi: 10.1258/jms.2012.011085. Epub 2012 Feb 22.
To estimate the pre-eclampsia screening performance of PAPP-A (pregnancy-associated plasma protein-A) and ADAM12 (A Disintegrin And Metalloprotease 12) in the early second trimester of pregnancy.
Stored frozen serum samples from a previously published nested case-control study comprising 77 women who developed pre-eclampsia and 224 unaffected controls were thawed and assayed for PAPP-A and ADAM12. Levels were converted into multiple of the unaffected median (MoM) values.
Neither PAPP-A or ADAM12 were significantly different in women who developed pre-eclamspia compared with unaffected controls (PAPP-A: 0.97 MoM [95% confidence interval 0.73 to 1.25], ADAM12: 1.01 MoM [0.91 to 1.13]).
Our results do not support the use of PAPP-A or ADAM12 in early second trimester antenatal screening for pre-eclampsia.
评估早孕期妊娠相关血浆蛋白 A（PAPP-A）和解整合素金属蛋白酶 12（ADAM12）用于子痫前期筛查的效能。
对先前发表的巢式病例对照研究中储存的冷冻血清样本进行解冻，该研究共纳入 77 例发生子痫前期的患者和 224 例无影响的对照者，检测 PAPP-A 和 ADAM12 的水平，并转化为无影响中位数的倍数（MoM）。
与无影响对照组相比，发生子痫前期的患者 PAPP-A 或 ADAM12 均无显著差异（PAPP-A：0.97 MoM [95%置信区间 0.73 至 1.25]，ADAM12：1.01 MoM [0.91 至 1.13]）。
我们的结果不支持在早孕期产前筛查中使用 PAPP-A 或 ADAM12 筛查子痫前期。
